NAD+ vs SS-31: Which Is Better? — Real Peptides

A 2019 study published in Cell Metabolism found that age-related NAD+ depletion correlates with a 50% reduction in mitochondrial function by age 60. But supplementing NAD+ precursors only partially restores that capacity. SS-31 (Elamipretide), a mitochondria-targeting peptide, operates through a completely different mechanism: it binds directly to cardiolipin on the inner mitochondrial membrane, preventing oxidative damage before the energy production machinery fails. The difference matters because NAD+ addresses the symptom (energy depletion), while SS-31 targets the structural vulnerability that causes the depletion in the first place.

Our team has worked with research institutions comparing these compounds across aging models, neurodegeneration protocols, and metabolic dysfunction studies. The decision between NAD+ and SS-31 isn't about which is 'better'. It's about matching the mechanism to the research question.

What's the difference between NAD+ and SS-31 for mitochondrial health?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular respiration and ATP production, declining 50% between ages 40–60. SS-31 (D-Arg-Dmt-Lys-Phe-NH₂) is a synthetic tetrapeptide that stabilizes cardiolipin, the phospholipid anchoring electron transport chain complexes to the inner mitochondrial membrane. NAD+ replenishes depleted energy substrates; SS-31 prevents membrane destabilization that triggers the energy crisis. They operate at different intervention points in mitochondrial decline.

The comparison isn't one-to-one. NAD+ boosting (via NMN, NR, or direct NAD+ administration) restores substrate availability for sirtuins and PARP enzymes, supporting DNA repair and metabolic regulation. SS-31 doesn't affect NAD+ levels. It preserves mitochondrial cristae structure, preventing cytochrome c release and reducing reactive oxygen species (ROS) generation at Complex I and III. Research models targeting neurodegeneration often combine both: NAD+ to restore bioenergetic capacity, SS-31 to prevent the oxidative membrane damage that NAD+ supplementation alone doesn't address. This article covers the distinct mechanisms each compound targets, what the clinical and preclinical evidence shows, and how research teams decide which to deploy based on the pathology being studied.

How NAD+ and SS-31 Target Mitochondrial Dysfunction Differently

NAD+ levels drop by approximately 50% between the fourth and sixth decades of life, correlating with reduced SIRT1 and SIRT3 activity. The sirtuins responsible for mitochondrial biogenesis and oxidative stress resistance. Supplementing NAD+ precursors (nicotinamide mononucleotide, nicotinamide riboside) raises intracellular NAD+ pools, reactivating sirtuin-dependent pathways that promote mitochondrial turnover via mitophagy and stimulate PGC-1α, the master regulator of mitochondrial biogenesis. The Cleveland Clinic's 2018 trial on NMN supplementation demonstrated a 40% increase in skeletal muscle NAD+ levels after 10 weeks, with corresponding improvements in insulin sensitivity. But no measurable change in mitochondrial membrane potential or ROS production.

SS-31 works at the structural level. Cardiolipin is a unique four-chain phospholipid found exclusively in the inner mitochondrial membrane, where it anchors the electron transport chain complexes (I, III, IV) and ATP synthase into supercomplexes called respirasomes. Oxidative damage to cardiolipin. Caused by hydroxyl radicals generated during electron leakage. Disrupts these supercomplexes, reducing ATP output and increasing ROS production in a self-reinforcing cycle. SS-31's four amino acids (D-Arg-Dmt-Lys-Phe-NH₂) bind selectively to cardiolipin with a dissociation constant of 20 nM, stabilizing the membrane and preventing lipid peroxidation. A 2016 Stealth BioTherapeutics Phase IIa trial in Barth syndrome. A genetic cardiolipin deficiency disorder. Showed that 40 mg SS-31 daily improved 6-minute walk distance by 21% after 12 weeks, a result NAD+ precursors have not replicated in comparable trials.

The mechanistic divergence is this: NAD+ boosts the cell's ability to produce more mitochondria and repair damaged ones, but it doesn't prevent the oxidative membrane damage that caused the original dysfunction. SS-31 prevents that membrane damage but doesn't restore depleted NAD+ pools or activate sirtuin pathways. In aging models where both NAD+ depletion and cardiolipin oxidation are present. Which is most of them. Neither compound alone fully restores mitochondrial function. Research protocols addressing Parkinson's disease, for example, often layer SS-31 to protect dopaminergic neurons from oxidative stress while using NAD+ precursors to support mitochondrial biogenesis in surviving cells.

Clinical and Preclinical Evidence: What the Data Actually Shows

NAD+ precursor trials have focused primarily on metabolic and age-related endpoints. The University of Colorado's 2018 randomized controlled trial on nicotinamide riboside (NR) in healthy older adults found that 1,000 mg daily for 6 weeks raised blood NAD+ levels by 60% but produced no significant change in blood pressure, arterial stiffness, or cognitive function compared to placebo. The 2021 University of Tokyo study on NMN showed a 4.7% improvement in insulin sensitivity at 250 mg daily after 10 weeks, but the effect disappeared within 4 weeks of stopping supplementation. NAD+ boosting consistently raises measurable NAD+ levels in blood and tissue, but translating those substrate increases into functional outcomes has been inconsistent across trials. The challenge is downstream: raising NAD+ doesn't guarantee that sirtuins, PARPs, and other NAD+-dependent enzymes will activate at therapeutically meaningful levels if other regulatory bottlenecks exist.

SS-31's clinical development has centered on diseases with confirmed mitochondrial dysfunction. The EMBRACÉ-HF trial (2020) tested SS-31 in heart failure patients with reduced ejection fraction, hypothesizing that cardiolipin stabilization would improve cardiac energetics. The trial missed its primary endpoint. 6-minute walk distance did not improve significantly. But secondary analyses found a 12% reduction in NT-proBNP (a biomarker of cardiac stress) and improved diastolic function in patients with baseline mitochondrial impairment measured via phosphocreatine recovery time. The Barth syndrome trial remains the strongest clinical evidence for SS-31, where the genetic cardiolipin deficiency creates a clearer mechanistic target. Preclinical models show more dramatic results: SS-31 reduced infarct size by 40–50% in rodent models of ischemia-reperfusion injury and extended lifespan in progeria mice by 30%, outcomes that NAD+ precursors have not matched in head-to-head comparisons.

The evidence gap is this: NAD+ precursors have been tested in broader populations (healthy aging, metabolic syndrome, mild cognitive impairment), while SS-31 trials have focused on severe mitochondrial pathologies (heart failure, Barth syndrome, primary mitochondrial myopathies). Comparing efficacy across those different patient populations is methodologically imprecise. What we can say from the existing data: NAD+ boosting produces measurable biochemical changes (increased NAD+ levels, sirtuin activation) but inconsistent clinical benefits. SS-31 produces smaller biochemical changes but more consistent functional improvements in populations with confirmed mitochondrial membrane defects. Neither compound has demonstrated efficacy in preventing age-related mitochondrial decline in healthy adults when used alone.

When Research Protocols Choose One Over the Other

NAD+ precursors are the default choice in research models where the primary pathology is bioenergetic depletion without severe oxidative membrane damage. This includes early-stage metabolic dysfunction (pre-diabetes, insulin resistance), mild cognitive impairment without neurodegeneration, and aging studies focused on healthspan rather than disease intervention. The rationale: if mitochondrial membranes are still structurally intact, restoring NAD+ pools can reactivate mitochondrial biogenesis and improve metabolic flexibility without needing membrane-targeted intervention. MK 677, a growth hormone secretagogue we offer, is often layered into these protocols to amplify IGF-1 signaling, which synergizes with NAD+-driven mitochondrial biogenesis.

SS-31 becomes the compound of choice when oxidative stress and membrane damage are the dominant features. Neurodegenerative disease models (Parkinson's, Alzheimer's, ALS), ischemia-reperfusion injury studies, and genetic mitochondrial disorders all show elevated cardiolipin peroxidation and cristae disruption on electron microscopy. Conditions where NAD+ supplementation alone has limited efficacy because the membrane damage prevents newly synthesized mitochondria from functioning properly. SS-31's ability to prevent cytochrome c release also makes it valuable in apoptosis-driven pathologies, where mitochondrial outer membrane permeabilization is the trigger for cell death cascades. Research teams working on traumatic brain injury models, for example, prioritize SS-31 because the acute oxidative burst after injury causes immediate cardiolipin oxidation. NAD+ levels may still be normal at that stage, so boosting them doesn't address the immediate pathology.

Combination protocols are increasingly common in aging and chronic disease research. The logic: NAD+ depletion and cardiolipin oxidation occur simultaneously in most age-related mitochondrial dysfunction, so targeting only one pathway leaves the other unaddressed. A 2022 preclinical study from the Buck Institute combined NMN (500 mg/kg) with SS-31 (3 mg/kg) in aged mice and found that the combination improved mitochondrial respiration by 38%. Compared to 18% for NMN alone and 22% for SS-31 alone. The synergy isn't additive; it's complementary. NAD+ precursors increase the number of functional mitochondria, while SS-31 ensures those mitochondria don't immediately suffer oxidative damage that would negate the biogenesis benefit.

NAD+ vs SS-31: Which Better Comparison

Key Takeaways

• NAD+ precursors restore depleted coenzyme levels and activate sirtuin-dependent mitochondrial biogenesis, but they do not prevent cardiolipin oxidation or stabilize mitochondrial membranes directly.
• SS-31 binds to cardiolipin on the inner mitochondrial membrane with a 20 nM dissociation constant, preventing oxidative damage to electron transport chain complexes and reducing ROS generation at the source.
• Clinical trials show NAD+ precursors raise blood NAD+ by 40–60% consistently, but functional endpoints (insulin sensitivity, cognitive function, arterial stiffness) have been inconsistent across studies.
• SS-31 demonstrated a 21% improvement in 6-minute walk distance in Barth syndrome patients and a 40–50% reduction in infarct size in rodent ischemia models. Outcomes NAD+ precursors have not replicated.
• Combination protocols using both NAD+ precursors and SS-31 produced 38% improvement in mitochondrial respiration in aged mice, compared to 18–22% for either compound alone, suggesting complementary rather than redundant mechanisms.
• NAD+ effects disappear within 4 weeks of stopping supplementation, while SS-31's cardiolipin stabilization persists as long as circulating peptide levels remain therapeutic. Both require continuous dosing for sustained benefit.

What If: NAD+ vs SS-31 Scenarios

What If You're Researching Early-Stage Metabolic Dysfunction Without Confirmed Oxidative Stress?

Start with NAD+ precursors. If mitochondrial membranes are structurally intact and the primary deficit is substrate depletion (low NAD+/NADH ratio, reduced sirtuin activity), restoring NAD+ pools will reactivate biogenesis pathways without requiring membrane-targeted intervention. Early-stage insulin resistance, pre-diabetes, and mild age-related energy decline typically don't show significant cardiolipin oxidation on lipidomics analysis. The mitochondria are underperforming due to insufficient NAD+ substrate, not structural damage. NMN at 500–1,000 mg daily or NR at 500 mg daily are standard starting points in metabolic research protocols.

What If the Model Shows Confirmed Mitochondrial Membrane Damage on Electron Microscopy?

SS-31 becomes the primary intervention. If cristae are disrupted, cardiolipin is oxidized, or cytochrome c is translocating to the cytosol, NAD+ supplementation alone won't restore function because the membrane architecture that houses the electron transport chain is compromised. This scenario is common in neurodegenerative disease models (Parkinson's, ALS), ischemic injury, and genetic mitochondrial disorders. SS-31 at 1–3 mg/kg in rodent models or 40 mg daily in human trials stabilizes the membrane first. Then, if needed, NAD+ precursors can be added to support biogenesis of new, protected mitochondria.

What If You're Designing a Longevity or Healthspan Study in Aged Subjects Without Disease?

Combine both, but expect modest outcomes. Aging populations show both NAD+ depletion and cardiolipin oxidation, but neither pathology is as severe as in disease states. So the absolute benefit from either compound is smaller. The Buck Institute's 2022 combination protocol (NMN + SS-31) in aged mice produced the largest functional gains, but even that was a 38% improvement in mitochondrial respiration, not a full restoration to youthful levels. In human healthspan studies, realistic expectations are a 10–20% improvement in metabolic markers and physical performance. Meaningful but not transformative. Longevity studies require multi-year timelines to detect mortality benefits, which neither compound has achieved in published human trials yet.

The Unvarnished Truth About NAD+ vs SS-31

Here's the honest answer: neither compound is a standalone solution for mitochondrial decline, and the 'which is better' framing misses the point. NAD+ precursors address one bottleneck (substrate depletion), SS-31 addresses a different bottleneck (membrane instability), and aging mitochondria have both problems simultaneously. The most robust preclinical data comes from combination protocols. Using NAD+ to drive biogenesis and SS-31 to protect the newly generated mitochondria from immediate oxidative damage. Single-agent trials show modest, inconsistent benefits because they're only addressing half the pathology. The research community is moving toward multi-target mitochondrial cocktails, not single-compound interventions, because that's what the biology demands. If your research question involves severe, acute mitochondrial damage (ischemia, neurodegeneration, genetic disorders), SS-31 is the more evidence-backed starting point. If you're studying metabolic aging or early dysfunction without oxidative pathology, NAD+ precursors are sufficient. For everything else. Which is most aging and chronic disease models. Both mechanisms need to be on the table.

The current limitation is that SS-31 requires parenteral administration (it degrades in the GI tract), making it less practical for long-term oral supplementation studies compared to NAD+ precursors. Oral SS-31 formulations with improved bioavailability are in development but not yet available for research use. That practical constraint shapes protocol design more than the mechanistic science does. Researchers often choose NAD+ precursors by default because they're easier to administer, not because they're more effective.

Our commitment to supporting cutting-edge mitochondrial research extends across our catalog. Researchers working on neuroprotection and cognitive enhancement protocols often explore compounds like Cerebrolysin and Dihexa, which address synaptic function and neuroplasticity. Mechanisms that intersect with mitochondrial bioenergetics in age-related cognitive decline. Every compound we supply undergoes rigorous third-party purity verification because mitochondrial research demands precision at the molecular level. When the science requires exact sequencing, contaminant-free synthesis, and consistent batch-to-batch reliability, that's the standard we've built Real Peptides around.

The comparison between NAD+ and SS-31 isn't about finding a winner. It's about matching the mechanism to the mitochondrial pathology you're studying. If your model shows energy depletion without membrane damage, NAD+ precursors restore substrate availability. If the membranes are oxidized and cristae are disrupted, SS-31 stabilizes the architecture that NAD+ alone can't repair. Most aging and disease models require both, which is why combination protocols are becoming the standard in serious mitochondrial research. The decision isn't which is better. It's which bottleneck you're addressing first, and whether the biology demands one mechanism or both.